[size=0.875]ArticlesVolume 407, Issue 10534p1147-1160March 21, 2026Download Full Issue
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trialJulio Rosenstock, MD[url=]a[/url],[url=]*[/url] Send email to [email protected] ∙ Daisuke Yabe, MD[url=]b[/url],[url=]c[/url],[url=]d[/url] ∙ David Cox, PhD[url=]e[/url] ∙ Jianghao Li, PhD[url=]e[/url] ∙ Max Denning, MD[url=]e[/url] ∙ Wen-Shuo Wu, MD[url=]e[/url] ∙ Rong Liu, PhD[url=]e[/url] ∙ Youna Zhao, PhD[url=]e[/url] for the ACHIEVE-3 Investigators[url=]†[/url] Show less
URL: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00202-3/abstract
DOI: https://doi.org/10.1016/S0140-6736(26)00202-3
Thank you
|
10
NILM applications: Literature review of learning approaches, recent developments and challenges
